<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532309</url>
  </required_header>
  <id_info>
    <org_study_id>CJFH-20150203-CAP</org_study_id>
    <nct_id>NCT02532309</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques</brief_title>
  <official_title>A 2-year, Open-label, Randomized Study to Evaluate the Efficacy of Rosuvastatin Dosing Adjustment by LDL-C Level Compared to That of 5mg Maintenance Dose in Chinese Patients With Carotid Atherosclerotic Plaques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Clinstech-med consulting Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China-Japan Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-year, open-label, randomized study to evaluate the efficacy of Rosuvastatin
      dosing adjustment by LDL-C level compared to that of 5mg maintenance dose in chinese patients
      with Carotid Atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 2-year, randomized, open-label, prospective, parallel-group study. It only be
      held in China-Japan Friendship Hospital. Subjects with Carotid Atherosclerosis Plaques who
      meet all inclusion and none of the exclusion criteria will be randomized in a 1:1 ratio to
      receive treatment of rosuvastatin (5 mg, 10mg, 20mg) dosing adjustment by LDL-c level or
      fixed dose 5 mg. The study will consist of two phases: the Screening/Baseline period（-1to
      week 0）and the Follow-up period(0 to month 24). The follow-up period will comprise seven
      visits.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Carotid Plaque Area</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>A comparison of the change in total Carotid Plaques area from the two treatment groups examined by color Doppler ultrasound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Carotid Plaque Area</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Reversal of total Carotid Atherosclerosis Plaques in the two rosuvastatin dose group at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Carotid Plaque Area</measure>
    <time_frame>Baseline to 12 months and 24 months</time_frame>
    <description>Changes from baseline in total Carotid Atherosclerosis Plaques (TPA) from the two rosuvastatin treatment groups from baseline at 12 months and 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Intima-Media Thickness(IMT)</measure>
    <time_frame>Baseline to 12 months and 24 months</time_frame>
    <description>Changes of Carotid Intima-Media Thickness (IMT) in the two rosuvastatin treatment groups from baseline to 12 months and to 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of Blood lipid</measure>
    <time_frame>baseline and 1, 2, 3, 6, 12, 18, 24 months post-dose</time_frame>
    <description>Changes from baseline in the level of Blood lipid from the two rosuvastatin treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein-cholesterol (LDL-c)</measure>
    <time_frame>Baseline to 12 months and 24 months</time_frame>
    <description>Analysis of the corrlation between LDL-c and TPA from the two rosuvastatin treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Intima-Media Thickness(IMT)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Analysis of the corrlation between IMT and TPA in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>The categories and incidences of Adverse Events from the two treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of Major Adverse Cardiovascular and Cerebrovascular Events（MACCE）</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Incidences of Major adverse cardiovascular and cerebrovascular events from the two rosuvastatin treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Carotid Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin dose adjustment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin fixed dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin (5mg，10mg，20mg)</intervention_name>
    <description>Rosuvastatin dose adjusted by LDL-c level( If LDL-C&gt;1.1mmol/L and &lt;1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.</description>
    <arm_group_label>Rosuvastatin dose adjustment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 5mg</intervention_name>
    <description>Rosuvastatin 5mg/day</description>
    <arm_group_label>Rosuvastatin fixed dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects or legal guardian can understand and sign the written informed consent form;

          -  LDL-C≥100mg/dl（2.6mmol/l）.

          -  Subjects with carotid atherosclerotic non-calcified plaques determined by color
             Doppler ultrasound on carotid. ( Plaque defined as limited intima media
             thickness≥1.5mm, according to the procedure of vascular ultrasound examination in 2009
             Chinese Journal of Ultrasonography )

          -  Subjects had not been treated with statins, or one had been treated with
             antihyperlipidemics no more than 3 months within 12 months prior to screening.

        Exclusion Criteria:

          -  Subjects known to be allergic to the study medication, or any components .

          -  Uncontrolled hypothyroidism defined as the systolic blood pressure(SBP) &gt;180 mmHg or
             the diastolic blood pressure(DBP) ＞100 mmHg.

          -  Concomitant with severe or frequent arrhythmia, such as Atrial Fibrillation, second or
             third degree Atrioventricular Block, Sick sinus Syndrome etc.

          -  Alanine aminotransaminase (ALT) and /or Aspartate aminotransferase (AST) &gt;1.5×ULN
             (upper limit of normal).

          -  Subjects with myopathies，or the value of Creatine kinase &gt;1.5×ULN (upper limit of
             normal).

          -  Concomitant with chronic wasting diseases, whose life span was anticipated no longer
             than 2 years.

          -  Pregnant or nursing woman, and subjects with a Pregnant plan during this study.

          -  Cognitive impairment, which may affect obtaining informed consent and participating in
             the study procedures.

          -  Unwilling to receive treatment or examinations outlined in protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cao Fei</last_name>
    <phone>86-10-56259183</phone>
    <email>frank.cao@clinstech-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu Wei, Ph.D</last_name>
      <email>63483495@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Jiao Jinsong, Professor</last_name>
      <email>jiaojinsong@aliyun.com</email>
    </contact_backup>
    <investigator>
      <last_name>Liu Wei, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2015</study_first_submitted>
  <study_first_submitted_qc>August 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>China-Japan Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Wei Liu</investigator_full_name>
    <investigator_title>Attending Doctor</investigator_title>
  </responsible_party>
  <keyword>Rosuvastatin</keyword>
  <keyword>Carotid Atherosclerosis plaque</keyword>
  <keyword>Crestor</keyword>
  <keyword>Rosuvastatin calcium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

